AI’s Outcomes Era: What Will Matter by 2031?

The growth in artificial intelligence (AI)-enabled medical devices has been exponential. According to the U.S. Food and Drug Administration (FDA), over 1,000 AI/machine learning (ML)-enabled medical devices had been authorized by 2024, reflecting a dramatic increase from fewer than 100 devices a decade earlier. 

Key characteristics of this landscape include:

• Radiology: Dominates (~76% of devices), reflecting the data-rich nature of imaging.¹ 
• Cardiovascular: Devices represent ~10%, driven by ECG and hemodynamic monitoring.¹
• Over 73% of AI devices are software-only, indicating a shift toward Software as a Medical Device (SaMD).¹

The third largest category of AI-based medtech is neurology, followed by hematology, gastroenterology-urology, ophthalmic, and anesthesiology.¹ This expansion is not just quantitative. It signals a transition toward routine clinical integration.

AI in medical technology has crossed a critical threshold. What began as a wave of pilots, largely in imaging, has matured into a growing portfolio of regulated products, embedded workflows, and reimbursable use cases. The next phase, through 2031, will not be defined by algorithmic novelty; it will be defined by measurable clinical outcomes, economic value, and seamless integration into care delivery.

For device makers, providers, and investors, the strategic question has shifted from “Does AI work?” to “Where does AI move outcomes and cost curves at scale?”

Why This Is Important

Regulatory momentum drives the transition. The FDA has now authorized hundreds of AI/ML-enabled medical devices, with a steep rise since 2018. While radiology still accounts for the majority, cardiology, neurology, and clinical decision support are expanding quickly.

This matters for two reasons. First, it signals regulatory normalization, which is a prerequisite for broad deployment. Second, it creates a crowded, competitive field where differentiation must come from outcomes and economics, not just accuracy metrics.

Clinical Evidence

Imaging and Early Disease Detection

AI has achieved its most robust clinical validation in imaging. Large-scale studies in breast cancer screening show that AI can increase cancer detection rates by 29% while reducing radiologist workload by 44%.² AI-based triage in pulmonary embolism and stroke imaging has demonstrated reductions in report turnaround time of ~22 minutes in real-world studies, improving time-to-treatment.³ These improvements translate directly into earlier diagnoses, reduced disease progression, and improved survival rates.

Cardiology and Predictive Monitoring

Cardiology is one of the fastest-growing AI segments. For example, AI-driven electrocardiogram algorithms detect arrhythmias such as atrial fibrillation with more than 90% sensitivity.⁴ Remote patient monitoring (RPM) systems using AI can reduce hospitalizations by optimizing triage and early intervention, particularly among cardiovascular populations.⁵ In FDA-reviewed RPM datasets, 74% of AI-enabled monitoring devices were cardiovascular-focused, highlighting a high clinical demand.⁶ The shift is fundamental—from episodic diagnostics to continuous, predictive care models.

Workflow Optimization and Clinical Efficiency

AI is also transforming clinical operations, such as AI triage and prioritization systems, which have shown statistically significant reductions in diagnostic turnaround time, particularly in radiology workflows. Clinical documentation tools, including AI-assisted transcription and summarization, reduce administrative burden, with studies reporting 30% to 50% time savings in documentation tasks.⁷ These gains indirectly improve patient outcomes by increasing clinician availability, reducing burnout, and improving care coordination. 

Economic Impact: Quantifying Value in Healthcare Systems

Healthcare stakeholders are increasingly focused on return on investment (ROI). AI contributes to cost savings through reduced unnecessary imaging and testing, prevention of hospital admissions via early detection, and optimized patient triage. AI-enabled remote monitoring systems specifically reduce costs by avoiding complications and hospitalizations through early intervention. McKinsey & Company research suggests that effectively deploying automation and analytics alone could eliminate $200 to $360 billion of spending in U.S. healthcare.⁸

AI improves the utilization of constrained healthcare resources. Radiology departments report 10% to 20% increases in throughput⁹ and AI-assisted scheduling and triage improve procedural efficiency.¹⁰ These gains enable higher patient volumes without proportional staffing increases and improved access to care.

AI aligns strongly with value-based care models and value-based reimbursement. Predictive models reduce readmissions and complications, and personalized treatment improves cost-effectiveness. This makes AI not just a clinical tool, but a financial lever for providers and payers.

Emerging Applications: What Will Define the Next Wave

Multimodal AI platforms are artificial intelligence systems capable of processing, understanding, and reasoning across multiple types of data or “modalities” simultaneously. Unlike traditional unimodal AI that handles only text or only images, these platforms integrate inputs such as text, images, audio, video, and sensor data to create a more comprehensive, human-like understanding of information. Next-generation systems integrate multiple data sources such as imaging, electronic health records (EHRs), genomics, and wearables. 

However, current FDA data shows that only 0.4% of AI devices use EHR data, and <1% use omics data, indicating a major growth opportunity. 

Personalized Medicine

AI is increasingly used to predict drug response, stratify patients for targeted therapies, and optimize treatment pathways. These applications are particularly impactful in oncology, where ineffective therapies can cost tens of thousands of dollars per patient.

Autonomous AI Systems

Regulators are beginning to approve fully autonomous AI systems, particularly in screening for diabetic retinopathy detection and AI-guided imaging acquisition. These tools expand access in rural settings and low-resource healthcare environments.

Continuous Remote Monitoring and Hospital-at-Home

AI is central to decentralized care, such as continuous monitoring via wearables, predictive alerts for deterioration, and AI-driven triage. These systems detect early clinical deterioration, personalize monitoring thresholds, and reduce inpatient demand.

Limitations and Risks: Evidence Gaps Remain

Despite rapid adoption, important challenges persist. There is limited clinical evidence for some devices. A recent analysis found only 1.6% of FDA-cleared AI devices reported randomized clinical trial data, and fewer than 8% reported prospective clinical studies.¹¹ This highlights a gap between regulatory clearance and robust clinical validation.

There is the potential for data bias and generalizability. AI models often rely on limited datasets and homogeneous populations. This raises concerns about performance variability across populations and health equity. In addition, model drift and real-world performance are concerns. Studies show AI model performance can degrade when applied to new clinical environments, with measurable declines in accuracy unless retrained on local data.¹²

There are also workflow integration challenges. Adoption depends heavily on ease of use and integration into clinical systems. Remember, even high-performing tools fail if they disrupt workflow.

What Will Define Winners by 2031

The next generation of AI-enabled medtech companies will be distinguished by four capabilities. The first strategic imperative is demonstrated clinical outcomes such as reduced mortality, fewer hospitalizations, and improved functional outcomes. In addition, proven economic value with a clear ROI for providers and payers and alignment with reimbursement models are critical to competitive advantage. Seamless integration will be required for the AI-based device to be embedded in clinical workflows with minimal friction for users. Finally, data scale and continuous learning will require large, diverse datasets and continuous model improvement.

Strategic Implications for the Medtech Industry

AI is fundamentally reshaping the competitive landscape. Traditional device companies are evolving into data-driven platforms, and AI-native startups are targeting high-value niches. Expect cross-industry partnerships between medtech, pharma, and tech to accelerate. Our industry is shifting from standalone devices to connected, intelligent systems that influence decisions and outcomes.

The Medi-Vantage Perspective

AI in medtech has reached a turning point. The evidence base is growing, regulatory pathways are maturing, and economic value is becoming clear. Yet the next phase will demand rigor, integration, and proof of real-world impact. By 2031, success will not be defined by the sophistication of algorithms, but by their ability to improve patient outcomes, reduce healthcare costs, and scale across real-world clinical environments. The transformation underway is profound. Healthcare is moving from reactive, episodic care to continuous, predictive, data-driven medicine. AI is not just enabling that transformation; it is becoming the infrastructure on which it is built.

References
¹ tinyurl.com/mpo260601
² tinyurl.com/mpo260602
³ tinyurl.com/mpo260603
⁴ tinyurl.com/mpo260604
⁵ tinyurl.com/mpo260605
⁶ tinyurl.com/mpo260606
⁷ tinyurl.com/mpo260607
⁸ tinyurl.com/mpo260608
⁹ tinyurl.com/mpo260609
¹⁰ tinyurl.com/mpo260610
¹¹ tinyurl.com/mpo260611
¹² tinyurl.com/mpo260612

MORE FROM THIS AUTHOR—SaMD: From Side Project to Central Strategy

Maria Shepherd has more than 20 years of experience in marketing in small startups and top-tier companies. She founded Medi-Vantage, which provides marketing and business strategy for the medtech industry. She can be reached at [email protected].